The bad news is it was on bardoxolone. Tweetorial catch-up here.
The CARDINAL Visual Abstract
Does Bardoxolone help patients with Alport’s Syndrome? Dr M Abdul Qader explains graphically.
Background
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
Background
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
Background
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
Background
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
